Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine (formerly EB-1020) for adult ADHD, Neurovance will develop centanafadine for adolescent and pediatric ADHD.
Hypothesis-driven, proprietary research at Neurovance discovered and developed centanafadine (CTN). Positive results from the first phase 2a clinical trial demonstrate efficacy and safety in adult ADHD, and a human abuse liability study suggests lower abuse potential and the potential for lower scheduling for CTN compared to stimulants used to treat adult ADHD.
ADHD is not just restless children. Studies show that adult drivers with ADHD are more likely to be in a serious car crash. Other research indicates that ADHD results in impulsiveness and impaired judgment that can increase problems ranging from unemployment to substance abuse to unwanted pregnancy. Untreated ADHD in adults makes navigating through life a significant challenge.